Millipore Sigma Vibrant Logo

364206 InSolution™ GM 6001 - Calbiochem

InSolution™ GM 6001, CAS 142880-36-2, is a 10 mM (1 mg/257 µl) solution of GM6001 in DMSO. A potent, cell-permeable, broad-spectrum inhibitor of MMPs.

InSolution™ GM 6001 - Calbiochem: Ficha de datos de seguridad (MSDS o SDS), certificado de análisis y de calidad (CoA y CoQ), expedientes, folletos y otros documentos disponibles.
Primary Target: MMP-1
View Products on Sigmaaldrich.com
364206
Ver precios y disponibilidad

Descripción

Replacement Information

Tabla espec. clave

Empirical Formula
C₂₀H₂₈N₄O₄

Precios y disponibilidad

Número de referencia DisponiblidadEmbalaje Cant./Env. Precio Cantidad
364206-1MG
Comprobando disponibilidad...
—
Disponibilidad a confirmar Disponibilidad a confirmar
Ingrese cantidad 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service

      		 Ampolla de plást. 1 mg
      Recuperando precio...
      No pudo obtenerse el precio
      La cantidad mínima tiene que ser múltiplo de
      Maximum Quantity is
      Al finalizar el pedido Más información
      Ahorró ()
       
      —
      Solicitar precio
      		 —
      Description
      Catalogue Number364206
      Brand Family Calbiochem®
      References
      ReferencesSolorzano, C.C., et al. 1997. Shock 7, 427.
      Galardy, R.E., et al. 1994. Ann. NY Acad. Sci. 732, 315.
      Galardy, R.E., et al. 1994. Cancer Res. 54, 4715.
      Galardy, R.E., et al. 1993. Drugs Future 18, 1109.
      Grobelny, D., et al. 1992. Biochemistry 31, 7152.
      Product Information
      ATP CompetitiveN
      FormLiquid
      FormulationA 10 mM (1 mg/257 µl) solution of GM6001 (Cat. No. 364205) in DMSO.
      Hill FormulaC₂₀H₂₈N₄O₄
      Chemical formulaC₂₀H₂₈N₄O₄
      Hygroscopic Hygroscopic
      ReversibleN
      Quality LevelMQ100
      Applications
      ApplicationInSolution™ GM 6001, CAS 142880-36-2, is a 10 mM (1 mg/257 µl) solution of GM6001 in DMSO. A potent, cell-permeable, broad-spectrum inhibitor of MMPs.
      Biological Information
      Primary TargetMMP-1
      Primary Target K<sub>i</sub>400 pM for MMP-1; 500 pM for MMP-2; 27 nM for MMP-3; 100 pM for MMP-8; and 200 pM for MMP-9
      Purity≥95% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Shipped with Blue Ice or with Dry Ice
      Toxicity Irritant
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Hygroscopic Hygroscopic
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial use, aliquot and refrigerate (4°C).
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de referencia GTIN
      364206-1MG 04055977213812

      Documentation

      Licencias necesarias

      Título
      PRODUCTO REGULADO POR LA SECRETARÍA DE SALUD

      InSolution™ GM 6001 - Calbiochem Ficha datos de seguridad (MSDS)

      Título

      Ficha técnica de seguridad del material (MSDS) 

      InSolution™ GM 6001 - Calbiochem Certificados de análisis

      CargoNúmero de lote
      364206

      Referencias bibliográficas

      Visión general referencias
      Solorzano, C.C., et al. 1997. Shock 7, 427.
      Galardy, R.E., et al. 1994. Ann. NY Acad. Sci. 732, 315.
      Galardy, R.E., et al. 1994. Cancer Res. 54, 4715.
      Galardy, R.E., et al. 1993. Drugs Future 18, 1109.
      Grobelny, D., et al. 1992. Biochemistry 31, 7152.

      Citas

      Título
    • K. Fredriksson, et al. (2006) Red blood cells increase secretion of matrix metalloproteinases from human lung fibroblasts in vitro. American Journal of Physiology Lung Cellular and Molecular Physiology 290, L326-L333.
    • Daniel W. Lambert, et al. (2005) Tumor Necrosis Factor- Convertase (ADAM17) Mediates Regulated Ectodomain Shedding of the Severe-acute Respiratory Syndrome-Coronavirus (SARS-CoV) Receptor, Angiotensin-converting Enzyme-2 (ACE2). Journal of Biological Chemistry 280, 30113-30119.
    • Haili Su, et al. (2005) Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation 112, 3157-3167.
      		•
      Ficha técnica

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision02-July-2008 RFH
      DescriptionA potent broad-spectrum hydroxamic acid inhibitor of matrix metalloproteinases (MMPs). Inhibits MMPs in vitro [Ki = 0.4 nM for skin fibroblast collagenase (MMP-1); Ki = 0.5 nM for gelatinase A (MMP-2); Ki = 27 nM for stromelysin (MMP-3); Ki = 0.1 nM for neutrophil collagenase (MMP-8); and Ki = 0.2 nM for gelatinase B (MMP-9)]. Also prevents the release of TNF-α in vivo and in vitro and abrogates endotoxin-induced lethality in mice.
      FormLiquid
      FormulationA 10 mM (1 mg/257 µl) solution of GM6001 (Cat. No. 364205) in DMSO.
      Intert gas (Yes/No) Packaged under inert gas
      Chemical formulaC₂₀H₂₈N₄O₄
      Purity≥95% by HPLC
      Storage Protect from light
      +2°C to +8°C
      Hygroscopic
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial use, aliquot and refrigerate (4°C).
      Toxicity Irritant
      ReferencesSolorzano, C.C., et al. 1997. Shock 7, 427.
      Galardy, R.E., et al. 1994. Ann. NY Acad. Sci. 732, 315.
      Galardy, R.E., et al. 1994. Cancer Res. 54, 4715.
      Galardy, R.E., et al. 1993. Drugs Future 18, 1109.
      Grobelny, D., et al. 1992. Biochemistry 31, 7152.
      Citation
    • K. Fredriksson, et al. (2006) Red blood cells increase secretion of matrix metalloproteinases from human lung fibroblasts in vitro. American Journal of Physiology Lung Cellular and Molecular Physiology 290, L326-L333.
    • Daniel W. Lambert, et al. (2005) Tumor Necrosis Factor- Convertase (ADAM17) Mediates Regulated Ectodomain Shedding of the Severe-acute Respiratory Syndrome-Coronavirus (SARS-CoV) Receptor, Angiotensin-converting Enzyme-2 (ACE2). Journal of Biological Chemistry 280, 30113-30119.
    • Haili Su, et al. (2005) Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation 112, 3157-3167.
      		•